FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

Data Compilation
#PharmaFlow

Pipeline Prospector 2025 highlights: FDA approves pill version of Novo’s Wegovy; BioMarin acquires Amicus for US$ 4.8 bn

Stock Recap
#PipelineProspector

Gemcitabine HCl

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

98 API Suppliers, 31 USDMF, 27 CEP/COS, 13 JDMF, 9 EU WC, 29 KDMF, 18 NDC API, 46 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

444 Drugs in Development

444 Drugs in Development

INTERMEDIATES

19 Intermediate Suppliers

19 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

277 FDF Dossiers, 92 FDA Orange Book, 115 Europe, 2 Canada, 4 Australia, 24 South Africa, 40 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 200MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 1200MG BASE/120ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1300MG BASE/130ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1400MG BASE/140ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1500MG BASE/150ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1600MG BASE/160ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1700MG BASE/170ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1800MG BASE/180ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1900MG BASE/190ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 2000MG BASE/200ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 13 SPI Pharma, 1 Gangwal Healthcare, 1 Pfanstiehl, 1 Kirsch Pharma, 1 Actylis, 1 BASF, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 1 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 12 Chewable & Orodispersible Aids, 10 Taste Masking, 10 Direct Compression, 7 Disintegrants & Superdisintegrants, 6 Parenteral, 3 Co-Processed Excipients, 3 Granulation, 1 Solubilizers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

3 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 127 News #PharmaBuzz

GLOBAL SALES INFORMATION

10 US Medicaid Prescriptions, 24 Regulatory FDF Prices, 2 Annual Reports

MARKET PLACE

17 APIs, 9 FDF Dossiers, 2 Intermediates

PATENTS & EXCLUSIVITIES

14 US Patents, 1 US Exclusivities

REF. STANDARDS & IMPURITIES

3 EDQM, 5 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/01/2026	Dr. Reddy's Laboratories	India	DR. REDDY'S LABORATORIES LIMITED Hyderabad IN	R1-CEP 2007-075 - Rev 06	Gemcitabine hydrochloride	2021-06-18	Valid	Chemical		2306
29/01/2026	TAPI Technology & API Services	Israel	TAPI NL B.V. Amsterdam NL	CEP 2008-161 - Rev 03	Gemcitabine hydrochloride	2025-05-05	Valid	Chemical		2306

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Gemcitabine HCl

Gemcitabine HCl

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

98 API Suppliers

31 USDMF

27 CEP/COS

13 JDMF

9 EU WC

29 KDMF

18 NDC API

46 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

444 Drugs in Development

INTERMEDIATES

19 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

277 FDF Dossiers

92 FDA Orange Book

115 Europe

2 Canada

4 Australia

24 South Africa

40 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 200MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

13 SPI Pharma

1 Gangwal Healthcare

1 Pfanstiehl

1 Kirsch Pharma

1 Actylis

1 BASF

2 Gangwal Chemicals

1 Ingredion Pharma Solutions

1 Kerry

2 Microlex e.U

1 Pluviaendo

3 Roquette

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders

12 Chewable & Orodispersible Aids

10 Taste Masking

10 Direct Compression

7 Disintegrants & Superdisintegrants

6 Parenteral

3 Co-Processed Excipients

3 Granulation

1 Solubilizers

1 Thickeners and Stabilizers

DIGITAL CONTENT

3 Data Compilation #PharmaFlow

1 Stock Recap #PipelineProspector

127 News #PharmaBuzz

GLOBAL SALES INFORMATION

10 US Medicaid Prescriptions

24 Regulatory FDF Prices

2 Annual Reports

MARKET PLACE

17 APIs

9 FDF Dossiers

2 Intermediates

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 200MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons